FTC Closes Review of Genzyme's Acquisition of Novazyme

14-Jan-2004

Genzyme Corp. announced yesterday that the Federal Trade Commission has closed its review of the company's acquisition of Novazyme Pharmaceuticals Inc. The FTC review sought to determine whether there were anti-competitive aspects of the transaction. Genzyme acquired Novazyme in September 2001. The acquisition did not require pre-merger notification under the Hart-Scott-Rodino Antitrust Improvements Act.

Genzyme Corporation is a global biotechnology company dedicated to making a major positive impact on the lives of people with serious diseases. The company's broad product portfolio is focused on rare genetic disorders, renal disease, osteoarthritis and immune-mediated diseases, and includes an industry-leading array of diagnostic products and services. Genzyme's commitment to innovation continues today with research into novel approaches to cancer, heart disease, and other areas of unmet medical need. More than 5,300 Genzyme employees in offices around the globe serve patients in over 80 countries.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances